<?xml version='1.0' encoding='utf-8'?>
<document id="28674251"><sentence text="Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants."><entity charOffset="21-32" id="DDI-PubMed.28674251.s1.e0" text="Fluvastatin" /><entity charOffset="95-106" id="DDI-PubMed.28674251.s1.e1" text="Fluvastatin" /><pair ddi="false" e1="DDI-PubMed.28674251.s1.e0" e2="DDI-PubMed.28674251.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28674251.s1.e0" e2="DDI-PubMed.28674251.s1.e1" /></sentence><sentence text="Fluvastatin, which is one of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins), is primarily metabolized by CYP2C9 and to a lesser extent by CYP3A4 and CYP2C8"><entity charOffset="0-11" id="DDI-PubMed.28674251.s2.e0" text="Fluvastatin" /></sentence><sentence text=" Predictions of drug-drug interactions (DDI) are important for the safety of combination therapies with statins, in particular drugs that are metabolized by CYP3A4" /><sentence text=" Little information is available regarding drug interactions with fluvastatin"><entity charOffset="66-77" id="DDI-PubMed.28674251.s4.e0" text="fluvastatin" /></sentence><sentence text=" Since CYP2C9 is a polymorphic enzyme, we investigated the effect of DDI via CYP2C9, CYP3A4, and CYP2C8 on fluvastatin pharmacokinetics by using a validated prediction method in relation to CYP2C9 variants"><entity charOffset="107-118" id="DDI-PubMed.28674251.s5.e0" text="fluvastatin" /></sentence><sentence text=" The predicted increases in the area under the concentration-time curve (AUC) ratios of fluvastatin in carriers with CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3, and CYP2C9*3/*3 versus that found in carriers with CYP2C9*1/*1 were 1"><entity charOffset="88-99" id="DDI-PubMed.28674251.s6.e0" text="fluvastatin" /></sentence><sentence text="16, 1" /><sentence text="35, 1" /><sentence text="37, 1" /><sentence text="65, and 2" /><sentence text="06, respectively" /><sentence text=" Our in silico model predicted that administration of fluvastatin in conjunction with the potent inhibitors that completely inhibited CYP3A4 and CYP2C8 in carriers with the CYP2C9*3/*3 variant would cause a 3"><entity charOffset="54-65" id="DDI-PubMed.28674251.s12.e0" text="fluvastatin" /></sentence><sentence text="23- and 2" /><sentence text="60-fold increase in the AUC ratios, respectively, when compared to that for the carriers with the CYP2C9*1/*1 taking fluvastatin alone"><entity charOffset="117-128" id="DDI-PubMed.28674251.s14.e0" text="fluvastatin" /></sentence><sentence text=" We also predicted the effect of telmisartan when coadministered with fluvastatin"><entity charOffset="33-44" id="DDI-PubMed.28674251.s15.e0" text="telmisartan" /><entity charOffset="70-81" id="DDI-PubMed.28674251.s15.e1" text="fluvastatin" /><pair ddi="false" e1="DDI-PubMed.28674251.s15.e0" e2="DDI-PubMed.28674251.s15.e0" /><pair ddi="false" e1="DDI-PubMed.28674251.s15.e0" e2="DDI-PubMed.28674251.s15.e1" /></sentence><sentence text=" Our prediction results showed that the interaction between telmisartan and fluvastatin via CYP enzymes were negligible in clinical situations"><entity charOffset="60-71" id="DDI-PubMed.28674251.s16.e0" text="telmisartan" /><entity charOffset="76-87" id="DDI-PubMed.28674251.s16.e1" text="fluvastatin" /><pair ddi="false" e1="DDI-PubMed.28674251.s16.e0" e2="DDI-PubMed.28674251.s16.e0" /><pair ddi="false" e1="DDI-PubMed.28674251.s16.e0" e2="DDI-PubMed.28674251.s16.e1" /></sentence><sentence text="" /></document>